文献速递白血病

阿西米尼单药一线治疗慢性期慢性髓性白血病:ASCEND研究结果

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.
PubMed 文献 · Blood · 2024-01-01

澳大利亚白血病与淋巴瘤学组开展的ASCEND研究评估阿西米尼一线治疗新诊断慢性期慢性髓性白血病(CP-CML)的疗效,101例患者起始接受阿西米尼40 mg每日两次,中位随访21个月(范围0-36),82/101例仍在继续用药;3个月早期分子学反应(BCR::ABL1≤10%)达93%(96%CI 86-97%),12个月内主要分子学反应达79%(95%CI 70-87%),无死亡,1例发生淋系急变。

要点

  • 阿西米尼40 mg每日两次一线治疗CP-CML,3个月早期分子学反应率93%,12个月内主要分子学反应率79%。
  • 中位随访21个月时82/101例仍在继续阿西米尼治疗,因不良事件停药者占6%。
  • 无死亡病例,1例发生淋系急变,1例出现2次脑血管事件,未报告其他动脉闭塞事件。

核心结论

  • 阿西米尼作为CP-CML一线治疗可获得高比例的分子学反应,耐受性良好,因毒性停药率低。

研究设计与样本

  • 澳大利亚白血病与淋巴瘤学组开展的单臂研究(ASCEND研究),纳入新诊断CP-CML患者,起始阿西米尼40 mg每日两次。
  • 治疗失败(3或6个月BCR::ABL1>10%,或12或18个月>1%)者加用伊马替尼、尼洛替尼或达沙替尼。
  • 次优反应(6个月BCR::ABL1 1%-10%,12个月>0.1%-1%,或18个月>0.01%-1%)者阿西米尼剂量增至80 mg每日两次。
  • 共101例患者,中位随访21个月(范围0-36)。
  • 试验注册号ACTRN12620000851965。

主要发现

  • 3个月早期分子学反应(BCR::ABL1≤10%)率为93%(96%CI 86-97%)。
  • 12个月内主要分子学反应率为79%(95%CI 70-87%)。
  • 24个月时分子学反应4.5的累积发生率为53%。
  • 82/101例患者继续阿西米尼治疗,停药最常见原因为不良事件(6%)、反应丧失(4%)和撤回知情同意(5%)。
  • 无死亡病例,1例发生淋系急变;1例出现2次脑血管事件,未报告其他动脉闭塞事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for patients with chronic-phase chronic myeloid leukemia (CP-CML) failing ≥2 prior lines of therapy. The Australasian Leukaemia and Lymphoma Group conducted the Asciminib Evaluation in Newly Diagnosed CML study to assess efficacy of asciminib for newly diagnosed CP-CML. Patients commenced asciminib 40 mg twice daily. Patients with treatment failure, defined as BCR::ABL1 of >10% at 3 or 6 months, or >1% at 12 or 18 months, received either imatinib, nilotinib, or dasatinib in addition to asciminib. In patients with suboptimal response, defined as levels of 1% to 10% at 6 months, >0.1% to 1% at 12 months, or >0.01% to 1% at 18 months, the asciminib dose was increased to 80 mg twice daily. With a median follow-up of 21 months (range, 0-36), 82 of 101 patients continue asciminib. Most common reasons for treatment discontinuation were adverse events (6%), loss of response (4%), and withdrawn consent (5%). There were no deaths; 1 patient developed lymphoid blast crisis. The coprimary end points were early molecular response (BCR::ABL1 of ≤10% at 3 months), achieved in 93% (96% confidence interval [CI], 86-97%), and major molecular response by 12 months achieved in 79%; (95% CI, 70-87%), respectively. Cumulative incidence of molecular response 4.5 was 53% by 24 months. One patient had 2 cerebrovascular events; no other arterial occlusive events were reported. Asciminib as frontline CP-CML therapy leads to high rates of molecular response with excellent tolerance and a low rate of discontinuation for toxicity. This trial was registered at https://www.anzctr.org.au/ as #ACTRN12620000851965.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yeung DT, Shanmuganathan N, Reynolds J, et al. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024. PMID: 39102630. doi:10.1182/blood.2024024657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。